Akero Therapeutics AKRO
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Akero Therapeutics (AKRO) Business Model and Operations Summary
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Key Insights
Akero Therapeutics (AKRO) Core Market Data and Business Metrics
Latest Closing Price
$38.64Market Cap
$3.11 BillionPrice-Earnings Ratio
-10.30Total Outstanding Shares
79.62 Million SharesTotal Employees
63Dividend
No dividendIPO Date
June 20, 2019SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
601 Gateway Boulevard, Suite 350, South San Francisco, CA, 94080
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-230.11 Million |
| Net Cash Flow, Continuing | $106.03 Million |
| Net Cash Flow | $106.03 Million |
| Net Cash Flow From Operating Activities, Continuing | $-230.11 Million |
| Net Cash Flow From Investing Activities | $-109.71 Million |
| Net Cash Flow From Financing Activities | $445.85 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Basic Earnings Per Share | $-3.75 |
| Diluted Average Shares | $67.14 Million |
| Net Income/Loss | $-252.06 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Net Income/Loss Available To Common Stockholders, Basic | $-252.06 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $678,000 |
| Comprehensive Income/Loss | $-251.38 Million |
| Comprehensive Income/Loss Attributable To Parent | $-251.38 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Current Assets | $770.38 Million |
| Noncurrent Liabilities | $36.02 Million |
| Wages | $1.17 Million |
| Equity | $750.11 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Accounts Payable | $9.03 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||